<SEC-DOCUMENT>0001015820-20-000077.txt : 20201218
<SEC-HEADER>0001015820-20-000077.hdr.sgml : 20201218
<ACCEPTANCE-DATETIME>20201218172036
ACCESSION NUMBER:		0001015820-20-000077
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20201218
DATE AS OF CHANGE:		20201218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QIAGEN N.V.
		CENTRAL INDEX KEY:			0001015820
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38332
		FILM NUMBER:		201401563

	BUSINESS ADDRESS:	
		STREET 1:		HULSTERWEG 82
		CITY:			PL VENLO
		STATE:			P7
		ZIP:			5912
		BUSINESS PHONE:		31-77-35566-00

	MAIL ADDRESS:	
		STREET 1:		HULSTERWEG 82
		CITY:			PL VENLO
		STATE:			P7
		ZIP:			5912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QIAGEN NV
		DATE OF NAME CHANGE:	19960531
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a2020december17release.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i44922389fa104189a7e18eb5fc74fef9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM 6-K </font></div><div style="margin-top:9pt;padding-left:216pt;padding-right:216pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:33%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Report of Foreign Private Issuer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Rule 13a-16 or 15d-16 under</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the monthly period ended December 31, 2020 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number 001-38332</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;__________________________________</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">QIAGEN N.V.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;__________________________________</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hulsterweg 82</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5912 PL Venlo</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Netherlands</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</font></div><div style="margin-top:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 40-F&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)&#58;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)&#58;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i44922389fa104189a7e18eb5fc74fef9_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i44922389fa104189a7e18eb5fc74fef9_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QIAGEN N.V.</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 6-K</font></div><div style="margin-top:9pt;text-align:center"><font><br></font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:82.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.738%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Item</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i44922389fa104189a7e18eb5fc74fef9_7" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i44922389fa104189a7e18eb5fc74fef9_10" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Index</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i44922389fa104189a7e18eb5fc74fef9_13" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></font></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i44922389fa104189a7e18eb5fc74fef9_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i44922389fa104189a7e18eb5fc74fef9_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2020, QIAGEN N.V. (NYSE&#58; QGEN&#59; Frankfurt, Prime Standard&#58; QIA) issued a press release announcing a EUR 400 million sustainability-linked credit facility. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. </font></div><div style="margin-top:9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i44922389fa104189a7e18eb5fc74fef9_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i44922389fa104189a7e18eb5fc74fef9_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.640%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QIAGEN N.V.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Roland Sackers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Roland Sackers</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; December 18, 2020</font></div><div style="margin-bottom:17pt;margin-top:17pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i44922389fa104189a7e18eb5fc74fef9_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i44922389fa104189a7e18eb5fc74fef9_4" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</a></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.793%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">No.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Press Release dated December 17, 2020</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i44922389fa104189a7e18eb5fc74fef9_16"></div><hr style="page-break-after:always"><div style="min-height:117pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</font></td></tr><tr style="height:81pt"><td colspan="9" style="padding:0 1pt"><div><img alt="qgennewheaderlogoa351a.jpg" src="qgennewheaderlogoa351a.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:678px"></div></td></tr></table></div></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:115%">QIAGEN underlines and innovates its commitment to sustainability with a EUR 400mn sustainability-linked credit facility</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">Interest rate is linked to company&#8217;s environmental, social and governance rating </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">Transaction was well received and significantly oversubscribed by eleven banks </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.15pt">QIAGEN will donate margin gains of improved ESG rating to sustainability-linked causes</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Venlo, Netherlands, December 17, 2020</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> - QIAGEN N.V. (NYSE&#58; QGEN&#59; Frankfurt Prime Standard&#58; QIA) announced today that it has successfully concluded a syndicated revolving credit facility for EUR 400mn with an interest rate linked to the company&#8217;s environmental, social and governance (ESG) performance. </font></div><div style="margin-bottom:17pt;margin-top:17pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The agreement makes QIAGEN the first provider of molecular diagnostics solutions with a sustainability component built into corporate borrowing. It underlines QIAGEN&#8217;s commitment to people and planet by creating financial incentives to further integrate sustainability throughout every part of its business.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The facility will run for three years and each lender will be able to extend this period by one year two times. It replaces a facility of the same amount that runs until December 2021 and will be used for general corporate purposes including potential acquisitions. One factor determining the new facility&#8217;s credit margin will be QIAGEN&#8217;s sustainability rating, as assigned by ISS-ESG. This independent and highly regarded sustainability-ratings agency in July 2020 awarded QIAGEN its top-flight &#8220;Prime&#8221; rating. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">&#8220;Our mission to make improvements in life possible includes sustainable business practices,&#8221; said Roland Sackers, Chief Financial Officer of QIAGEN. &#8220;By linking this new credit facility to our sustainability rating, we are creating a new incentive to further foster and embed sustainability in all business areas. An improved ESG rating triggers interest-margin gains and QIAGEN will donate any money saved this way to sustainable causes.&#8221; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The syndicated credit facility is provided by a group of eleven core relationship banks and syndication was significantly oversubscribed. Deutsche Bank AG and UniCredit Bank AG were mandated as coordinators with Deutsche Bank AG acting as the Documentation and Facility Agent and UniCredit Bank AG as the sustainability coordinator.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:115%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">QIAGEN&#8217;s commitment to sustainability is integrated across all business areas and aims to exceed the standards of environmental and labor laws. The company is dedicated to reducing the environmental impact of our operations, to being socially responsible to communities, and to fostering a diversity that allows all employees to develop. Goals include reducing CO2 emissions in line with a target to keep global warming to 1.5C, ridding products and packaging of single-use plastics, providing healthy, high-performance workplaces, and making improvements in life possible through the products we provide.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">More on QIAGEN&#8217;s sustainability initiatives can be found </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">here</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i44922389fa104189a7e18eb5fc74fef9_19"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">About QIAGEN</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&#38;D and industrial applications, primarily forensics). As of September 30, 2020, QIAGEN employed more than 5,300 people in over 35 locations worldwide. Further information can be found at </font><font style="color:#0e32e1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">http&#58;&#47;&#47;www.qiagen.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Forward-Looking Statement</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, including those products used in the response to the COVID-19 pandemic, timing for launch and development, marketing and&#47;or regulatory approvals, financial and operational outlook, growth and expansion, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics&#59; changing relationships with customers, suppliers and strategic partners&#59; competition&#59; rapid or unexpected changes in technologies&#59; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors)&#59; our ability to obtain regulatory approval of our products&#59; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products&#59; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products&#59; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses&#59; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, including the breadth and duration of the COVID-19 pandemic and its impact on the demand for our products and other aspects of our business, or other force majeure events&#59; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected&#59; and the other factors discussed under the heading &#8220;Risk Factors&#8221; contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Contacts</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">John Gilardi</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Vice President Corporate Communications and Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">+49 2103 29 1171 and +49 152 018 11711 and +1 240 686 2222 &#47; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">john.gilardi&#64;qiagen.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Phoebe Loh</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Director Investor Relations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">+49 2103 29 11457 &#47; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">phoebe.loh&#64;qiagen.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Dr. Thomas Theuringer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Senior Director, Head of External Communications </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">+49 2103 29 11826 &#47; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">thomas.theuringer&#64;qiagen.com</font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline"> </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Robert Reitze</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Senior Manager Public Relations </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:102%">+49 2103 29 11676 &#47; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:102%">robert.reitze&#64;qiagen.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>qgennewheaderlogoa351a.jpg
<TEXT>
begin 644 qgennewheaderlogoa351a.jpg
M_]C_X  02D9)1@ ! 0$       #_[@ .061O8F4 9      !_^$ %D5X:68
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M P,# P,#_\  $0@ : ,@ P$1  (1 0,1 ?_$ !T  0 " @(#
M   ("08' 0H#! 7_Q  Z$  ! P,"!0,# P(#" ,      P0% 08' @@3UA>7
M6!$4"2$C%1(S%C%!(D,D4<%38Y,TA HF&$C_Q  = 0$  P # 0$!
M    !08' P0( @$)_\0 5!$!  $" @4) P4*"0D)      ,$!0$"$1,4!@<A
M$B.CTU25%U<Q,PA!42*#%6&!D3)#4V-S)!;P<:'!0I,T1 FQX6*"DK*S9#71
M\5)RPH24577_V@ , P$  A$#$0 _ ._P
M
M
M
M
M
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M#ER\R?YOG;$(9,
M
M&J<JVNK<$8V>-ED$G$-I=JUHZ51;H:VCC0E5S^IPXUZ4$:IZFVC5ZZ_\)8-W
M;K%;:O')488ZB7###'Y?9_WJ_O#;)*ZEPDB_&CY6IL6VRG.2>B:1DX1]%QFM
MPBKJAYN-F=>MYK352JUJK%.WB"%4*5^Y13ZU_L6?>6[[)1['JY]IE_.Q:O\
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MO3=&FT-4G;GYG53B:6'\DATY!1M_7W7XKW?YS@?^,3OVU2[!]HZN;9OU4O\
MQ/=]8B?LFJVW[/TP[1^MCT_@]XSO)-ETB(^/F:2D<A&Q<4PBI!S+R#"(2T:V
MB=4DG7N)-9%EZ+>G[55*?4@K!?-?GEI<8\<:F:?6]%AC)CR_)HT?)\^A+7NR
M2Q11RPR?L\,&K9-AZV%&>E2Y57;)PG(,O:L/QS]I(M];;4HBLLK5PQ5<,ZUU
M*(Z/3AZZT^A'[SW>"KQRT$&&/-BQ^7#'#'YO9CAAC\ORN[NS;9J;#&LET:9<
M&]BHK<
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MS\S'ZQ8N$]3785U328_],PBP^]+IPT8_Z^3G_P!6N:/.C<P
M
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M_4%38I:*&@O-+AA+HAT\RHC]WCG^GIEZ/Z&&.LDDQT9X_I_(OG/-;TD
M
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M9*VFH*^HPY,=&CF1TV,>,FG#ECUG,P_.8+%M]7Q 6MN7IAY79/G3%%TWSAC
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M4DF,$L<&>FRXY9,^HFDCR99^=CFBS9]7IR9,N,7RXZ78%/.S<P
M
M                                0S<9RW2).%DF^R"ZWB":ZNA%UISQ
M@QO1=/0I^E)Q5%6XZ+(T62I_2OU(G-5W33_8<?ZV-ND'#G@W)'TW$2BBQ_\
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M6FT2XY]95YX)JC+%HCS9LFF&GRYI<^&?/AEC^AEQYO/Y^;Z.7,C/7.VZJO\
M^%KM[_X)_P!URT(O;KG\M%UT;6<>&W!K'V<1J+P:\=BXZ[;JO!>[._\ @GF8
M;=<NX];&_/+;@UZCT7@UY[$Z[;JO!>[._P#@GF8;=<NX];&>6W!KU'HO!KSV
M)UVW5>"]V=_\$\S#;KEW'K8SRVX->H]%X->>Q.NVZKP7NSO_ ()YF&W7+N/6
MQGEMP:]1Z+P:\]B==MU7@O=G?_!/,PVZY=QZV,\MN#7J/1>#7GL3KMNJ\%[L
M[_X)YF&W7+N/6QGEMP:]1Z+P:\]B==MU7@O=G?\ P3S,-NN7<>MC/+;@UZCT
M7@UY[$Z[;JO!>[._^">9AMUR[CUL9Y;<&O4>B\&O/8G7;=5X+W9W_P $\S#;
MKEW'K8SRVX->H]%X->>Q.NVZKP7NSO\ X)YF&W7+N/6QGEMP:]1Z+P:\]B==
MMU7@O=G?_!/,PVZY=QZV,\MN#7J/1>#7GL3KMNJ\%[L[_P"">9AMUR[CUL9Y
M;<&O4>B\&O/8G7;=5X+W9W_P3S,-NN7<>MC/+;@UZCT7@UY[$Z[;JO!>[._^
M">9AMUR[CUL9Y;<&O4>B\&O/8G7;=5X+W9W_ ,$\S#;KEW'K8SRVX->H]%X-
M>>Q.NVZKP7NSO_@GF8;=<NX];&>6W!KU'HO!KSV)UVW5>"]V=_\ !/,PVZY=
MQZV,\MN#7J/1>#7GL3KMNJ\%[L[_ .">9AMUR[CUL9Y;<&O4>B\&O/8G7;=5
MX+W9W_P3S,-NN7<>MC/+;@UZCT7@UY[$Z[;JO!>[._\ @GF8;=<NX];&>6W!
MKU'HO!KSV)UVW5>"]V=_\$\S#;KEW'K8SRVX->H]%X->>Q.NVZKP7NSO_@GF
M8;=<NX];&>6W!KU'HO!KSV)UVW5>"]V=_P#!/,PVZY=QZV,\MN#7J/1>#7GL
M3KMNJ\%[L[_X)YF&W7+N/6QGEMP:]1Z+P:\]B==MU7@O=G?_  3S,-NN7<>M
MC/+;@UZCT7@UY[$Z[;JO!>[._P#@GF8;=<NX];&>6W!KU'HO!KSV)UVW5>"]
MV=_\$\S#;KEW'K8SRVX->H]%X->>Q.NVZKP7NSO_ ()YF&W7+N/6QGEMP:]1
MZ+P:\]B==MU7@O=G?_!/,PVZY=QZV,\MN#7J/1>#7GL3KMNJ\%[L[_X)YF&W
M7+N/6QGEMP:]1Z+P:\]B==MU7@O=G?\ P3S,-NN7<>MC/+;@UZCT7@UY[$Z[
M;JO!>[._^">9AMUR[CUL9Y;<&O4>B\&O/8G7;=5X+W9W_P $\S#;KEW'K8SR
MVX->H]%X->>Q.NVZKP7NSO\ X)YF&W7+N/6QGEMP:]1Z+P:\]B==MU7@O=G?
M_!/,PVZY=QZV,\MN#7J/1>#7GL3KMNJ\%[L[_P"">9AMUR[CUL9Y;<&O4>B\
M&O/8G7;=5X+W9W_P3S,-NN7<>MC/+;@UZCT7@UY[$Z[;JO!>[._^">9AMUR[
MCUL9Y;<&O4>B\&O/8G7;=5X+W9W_ ,$\S#;KEW'K8SRVX->H]%X->>Q.NVZK
MP7NSO_@GF8;=<NX];&>6W!KU'HO!KSV)UVW5>"]V=_\ !/,PVZY=QZV,\MN#
M7J/1>#7GL3KMNJ\%[L[_ .">9AMUR[CUL9Y;<&O4>B\&O/8G7;=5X+W9W_P3
MS,-NN7<>MC/+;@UZCT7@UY[$Z[;JO!>[._\ @GF8;=<NX];&>6W!KU'HO!KS
MV)UVW5>"]V=_\$\S#;KEW'K8SRVX->H]%X->>Q.NVZKP7NSO_@GF8;=<NX];
M&>6W!KU'HO!KSV)UVW5>"]V=_P#!/,PVZY=QZV,\MN#7J/1>#7GL3KMNJ\%[
ML[_X)YF&W7+N/6QGEMP:]1Z+P:\]B==MU7@O=G?_  3S,-NN7<>MC/+;@UZC
MT7@UY[$Z[;JO!>[._P#@GF8;=<NX];&>6W!KU'HO!KSV)UVW5>"]V=_\$\S#
M;KEW'K8SRVX->H]%X->>Q.NVZKP7NSO_ ()YF&W7+N/6QGEMP:]1Z+P:\]B=
M=MU7@O=G?_!/,PVZY=QZV,\MN#7J/1>#7GL3KMNJ\%[L[_X)YF&W7+N/6QGE
MMP:]1Z+P:\]B==MU7@O=G?\ P3S,-NN7<>MC/+;@UZCT7@UY[$Z[;JO!>[._
M^">9AMUR[CUL9Y;<&O4>B\&O/8G7;=5X+W9W_P $\S#;KEW'K8SRVX->H]%X
M->>Q.NVZKP7NSO\ X)YF&W7+N/6QGEMP:]1Z+P:\]B==MU7@O=G?_!/,PVZY
M=QZV,\MN#7J/1>#7GL3KMNJ\%[L[_P"">9AMUR[CUL9Y;<&O4>B\&O/8G7;=
M5X+W9W_P3S,-NN7<>MC/+;@UZCT7@UY[$Z[;JO!>[._^">9AMUR[CUL9Y;<&
MO4>B\&O/8G7;=5X+W9W_ ,$\S#;KEW'K8SRVX->H]%X->>Q.NVZKP7NSO_@G
MF8;=<NX];&>6W!KU'HO!KSV)UVW5>"]V=_\ !/,PVZY=QZV,\MN#7J/1>#7G
ML3KMNJ\%[L[_ .">9AMUR[CUL9Y;<&O4>B\&O/8G7;=5X+W9W_P3S,-NN7<>
MMC/+;@UZCT7@UY[$Z[;JO!>[._\ @GF8;=<NX];&>6W!KU'HO!KSV)UVW5>"
M]V=_\$\S#;KEW'K8SRVX->H]%X->>Q.NVZKP7NSO_@GF8;=<NX];&>6W!KU'
MHO!KSV)UVW5>"]V=_P#!/,PVZY=QZV,\MN#7J/1>#7GL3KMNJ\%[L[_X)YF&
MW7+N/6QGEMP:]1Z+P:\]B==MU7@O=G?_  3S,-NN7<>MC/+;@UZCT7@UY[$Z
M[;JO!>[._P#@GF8;=<NX];&>6W!KU'HO!KSV)UVW5>"]V=_\$\S#;KEW'K8S
MRVX->H]%X->>Q.NVZKP7NSO_ ()YF&W7+N/6QGEMP:]1Z+P:\]B==MU7@O=G
M?_!/,PVZY=QZV,\MN#7J/1>#7GL3KMNJ\%[L[_X)YF&W7+N/6QGEMP:]1Z+P
M:\]B==MU7@O=G?\ P3S,-NN7<>MC/+;@UZCT7@UY[$Z[;JO!>[._^">9AMUR
M[CUL9Y;<&O4>B\&O/8G7;=5X+W9W_P $\S#;KEW'K8SRVX->H]%X->>Q.NVZ
MKP7NSO\ X)YF&W7+N/6QGEMP:]1Z+P:\]B==MU7@O=G?_!/,PVZY=QZV,\MN
M#7J/1>#7GL3KMNJ\%[L[_P"">9AMUR[CUL9Y;<&O4>B\&O/8G7;=5X+W9W_P
M3S,-NN7<>MC/+;@UZCT7@UY[$Z[;JO!>[._^">9AMUR[CUL9Y;<&O4>B\&O/
M8G7;=5X+W9W_ ,$\S#;KEW'K8SRVX->H]%X->>Q3-)EA   T)N0VSX:W98PE
M,0YSM!K>%F22[>010U+N6$K!SC+0NG'W%;LRP6;R$--L$W2NE-9+73]2:BB2
ME%$5%4]?2N%OIKE38TU3AIR8M'X4\6M_^">^=/OYPXK\U!?X,N.3''FX9XYH
ML^C603Q9OH2PR88?2R9\,=&;#))DYLF3+FPIUD?_ %Y=O6MY"ST1N6W2Z;ML
MR5MASCF=NRX[%O-&Q(>UYK1,,(.*BGMD,$E4&ZNFM6_ZE-+=!;T4J@I2NO0I
M6,=RZ;^A43X??TO=]/\ XH?%'9JFV5FZ.Y?V-<(JG"NBIZ6JI\:R2ICU>>27
M/M4N/+AHQS\F,DG+AC+AHR<R0K7X2MGBM^-\AW3(Y9O>54S MG6XH*Y;GMY6
MR+PR*\E4YF2>W':3&T&4>^AY!W11-1CZT1]HX60_;5UTKWL=T[9FEUN;&3'-
MS^=^-\OX&62_X@G'C)NWFW7L\=CMU%A8?L:&:GIIL*NGH,(]5DCAJ9*F3/EE
MR9-&B?EDUF2.33S\F&+=6=OBOV99_N+&ESW!B^,LF0QA(RCR/0Q3%6Q849=;
M.:K#4E8#(,7'6\JPO" ?-H?VRC9RG^FK-VZ0]>&X4I7LUF[MKJ\V7-ADU6.3
MV<SZ*@\./C)X_<,[7=K1;;U47&DN\<>$F-REJ*V2"2+6ZNHHY))\,]-49,9.
M?A)DQTZV.*31SX\F.$0*?^OYM!3FEFC;*&YQIAUU-Z)][M^0RFUTXR=NDUT'
M.EDOIK;E;D5C^*T1KQ-;[5)_;I_K"._<ZW:W\>79?S>GD_"W3-_B;<=9;=%/
M46G="3?^&'5Y+YC;</M##+_XO>[-CG^YJ-G_ .7;YRA\..TS)63-&5&,MFC$
MMP-;)M/'<4PPGD7IS!0MFV7 QMN04!%M8V%6?-HY*/AVU5$_<UHJJE377ZG:
MJMU[?4RZW)C)%C_H8Z/YF:[G?'?QOW2W/S;EU46[][MLEQJJ^3/=:#;I9:RL
MFDGFGSXR389<9,9)<^.&/,P]OL;OV_\ Q\8:VZY3RAENV+FR=>4_EW&N+L5W
MA&Y.GX*[H5Q;.*+,@[$A%J?_ !B.FY"8FH.!3K*KR+U]I=K**5IH3T5HG3MT
M5DIJ*62;+GDDQDAU>//QYW)^#!G7$_XF]_\ BIN;:-R;O2V>@MUDO-?<Z>2@
MAGIY<*BX54U7+_><\<>2*2;-A3X01Q:O+ERX8XY]&EX]FOQVX#V*W3G>Y,%N
MKW;M<^S=NS$Y:=QRL)(6M9B-J/[V?04%8+>.MR(EX^#9Z+[<H4T2+R47X*"%
M**TU:5-2OW;;-26K/)FI=.&$F.G%S<>?BDXE?$99MV[3Q%CMF-1NS33115--
M%-'45>:HCHXYIZW&2HFBSSY]CCSXXT\5-'S\\O1\W')ER3Q)9YO
M
M
M
M
M
M
M
4                       !_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
